Rate My Professor Miriam Rademaker

Rademaker has made substantial contributions to cardioendocrinology through preclinical ovine models of heart failure, authoring over 120 publications cited more than 2,900 times. Notable works include "Combined inhibition of phosphodiesterases-5 and -9 in experimental heart failure" (JACC: Heart Failure, 2024), "Phosphodiesterase 9 inhibition combined with valsartan and with sacubitril/valsartan in experimental ovine heart failure" (Journal of the American Heart Association, 2024), and "Haemodynamic, hormonal and renal actions of osteocrin in normal sheep" (Experimental Physiology, 2024). She has secured Heart Foundation of New Zealand project grants, such as $154,802 in 2020 for phosphodiesterase-9 inhibition versus/plus neprilysin inhibition in experimental heart failure, and $152,100 in 2017 for phosphodiesterase 9 inhibition in heart failure. Additionally, she is a member of the Christchurch School of Medicine Faculty and the Canterbury Medical Research Society, and serves on the editorial boards of the American Journal of Physiology: Regulatory, Integrative and Comparative Physiology and Clinical Science.